Perkenalan
Halaman ini memberikan analisis komprehensif tentang riwayat insider trading yang diketahui di Versant Vantage I GP, L.P.. Insider adalah pejabat, direktur, atau investor penting dalam suatu perusahaan. Adalah ilegal bagi insider untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik dan non-publik. Hal ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan ke SEC melalui Formulir 4. Meskipun ada pembatasan ini, penelitian akademis menunjukkan bahwa insider – secara umum – cenderung mengungguli pasar di perusahaan mereka sendiri.
Profitabilitas Perdagangan Rata-rata
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari seluruh pembelian pasar terbuka yang dilakukan oleh insider dalam 3 tahun terakhir. Untuk menghitungnya, kami memeriksa setiap pembelian pasar terbuka dan tidak terencana yang dilakukan oleh insider, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata perdagangan tersebut selama 3, 6, dan 12 bulan, merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami menghitung rata-rata semua metrik kinerja untuk menghitung metrik kinerja bagi insider. Daftar ini hanya mencakup insider yang telah melakukan setidaknya tiga perdagangan dalam 2 tahun terakhir.
Jika profitabilitas perdagangan insider ini adalah "T/A", maka insider tersebut belum melakukan pembelian di pasar terbuka dalam 3 tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang dapat diandalkan.
Frekuensi Pembaruan: Harian
Perusahaan dengan Posisi Insider yang Dilaporkan
Pengajuan SEC menunjukkan Versant Vantage I GP, L.P. telah melaporkan kepemilikan atau perdagangan di perusahaan berikut:
| Keamanan | Judul | Kepemilikan Terbaru yang Dilaporkan |
|---|---|---|
| US:LVTX / LAVA Therapeutics N.V. | 10% Owner | 0 |
| US:GLUE / Monte Rosa Therapeutics, Inc. | 10% Owner | 1.573.453 |
| 10% Owner | 148.312 | |
| US:OYST / Oyster Point Pharma Inc | 10% Owner | 0 |
| US:RPTX / Repare Therapeutics Inc. | 10% Owner | 0 |
| 10% Owner | 0 | |
| US:APRE / Aprea Therapeutics, Inc. | 10% Owner | 0 |
| US:PASG / Passage Bio, Inc. | 10% Owner | 0 |
Bagaimana Menafsirkan Grafik
Bagan berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka dan tidak terencana yang dilakukan oleh Versant Vantage I GP, L.P.. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham dipetakan sebagai persentase perubahan kumulatif harga saham. Misalnya, jika perdagangan insider dilakukan pada tanggal 1 Januari 2019, grafik akan menunjukkan persentase perubahan harian sekuritas hingga hari ini. Jika harga saham naik dari $10 menjadi $15 selama waktu ini, persentase perubahan harga saham kumulatif akan menjadi 50%. Perubahan harga dari $10 menjadi $20 adalah 100%, dan perubahan harga dari $10 menjadi $5 adalah -50%.
Pada akhirnya, kami mencoba untuk menentukan seberapa dekat korelasi perdagangan insider dengan keuntungan berlebih (positif atau negatif) pada harga saham untuk melihat apakah insider mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi insider. Pertimbangkan situasi di mana insider melakukan hal ini. Dalam situasi ini, kita mengharapkan (a) keuntungan positif setelah pembelian, atau (b) keuntungan negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, yang menunjukkan keuntungan positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, yang menunjukkan keuntungan negatif setelah setiap transaksi penjualan.
Namun, hal ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam kenaikan non-siklus selama bertahun-tahun, maka kita perkirakan semua lahan pasca pembelian akan miring ke atas. Demikian pula, penurunan non-siklus selama bertahun-tahun akan mengakibatkan penurunan pasca-perdagangan. Tak satu pun dari grafik ini menunjukkan aktivitas insider trading.
Indikator terkuat adalah situasi di mana harga saham sangat bersiklus, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat memberi isyarat kepada insider yang mengatur waktu perdagangan demi keuntungan finansial mereka.
Pembelian Insider APRE / Aprea Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada APRE / Aprea Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-10-07 | APRE | Versant Vantage I, L.P. | 333.333 | 15,0000 | 16.667 | 300,0000 | 4.999.995 | 81 | 990.6 | 11.509.345 | 230,19 |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider APRE / Aprea Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di APRE / Aprea Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider GLUE / Monte Rosa Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada APRE / Aprea Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-06-28 | GLUE | Versant Venture Capital VI, L.P. | 157.895 | 19,0000 | 157.895 | 19,0000 | 3.000.005 | 67 | 42.21 | 3.664.743 | 122,16 |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider GLUE / Monte Rosa Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di APRE / Aprea Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Pembelian Insider PASG / Passage Bio, Inc. - Analisis Keuntungan Jangka Pendek
Di bagian ini, kami menganalisis profitabilitas setiap pembelian insider di pasar terbuka yang tidak direncanakan dan dilakukan pada APRE / Aprea Therapeutics, Inc.. Analisis ini membantu untuk memahami apakah insider secara konsisten menghasilkan keuntungan yang tidak normal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan pembelian pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Pengembalian Maksimal (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-03-03 | PASG | Versant Venture Capital VI, L.P. | 225.000 | 18,0000 | 11.250 | 360,0000 | 4.050.000 | 112 | 36.07 | -3.644.212 | -89,98 |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Penjualan Insider PASG / Passage Bio, Inc. - Analisis Kerugian Jangka Pendek
Di bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan insider di pasar terbuka yang tidak direncanakan dan dilakukan di APRE / Aprea Therapeutics, Inc.. Pola penghindaran kerugian yang konsisten mungkin menunjukkan bahwa transaksi penjualan pada masa depan dapat memprediksi penurunan harga. Analisis ini dilakukan selama satu tahun setelah setiap perdagangan dan hasilnya bersifat teoretis .
Tabel berikut ini menunjukkan penjualan pasar terbuka terkini yang bukan merupakan bagian dari rencana perdagangan otomatis.
| Tanggal Perdagangan | Kode | Insider | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari ke Minimal |
Harga di Minimal |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
|---|---|---|---|---|---|---|---|
| Tidak ada perdagangan pasar terbuka yang tidak direncanakan untuk kombinasi insider dan keamanan ini |
Harga yang Disesuaikan adalah harga yang disesuaikan secara terpisah. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pembagiannya.
Riwayat Insider Trading
Tabel ini menunjukkan daftar lengkap perdagangan insider yang dilakukan oleh Versant Vantage I GP, L.P. sebagaimana diungkapkan kepada Securities Exchange Commission (SEC).
| Tanggal Berkas | Tanggal Trans | Formulir | Kode | Keamanan | Kode | Saham | Sisa Saham | Persen Mengubah |
Saham Harga |
Trans Nilai |
Tersisa Nilai |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-23 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -532.870 | 0 | -100,00 | 1,40 | -746.764 | ||
| 2025-09-23 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -2.370.533 | 0 | -100,00 | 1,40 | -3.322.065 | ||
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -228.791 | 532.870 | -30,04 | 1,44 | -329.871 | 768.292 | |
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -366.111 | 2.370.533 | -13,38 | 1,44 | -527.859 | 3.417.834 | |
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -226.726 | 761.661 | -22,94 | 1,49 | -337.640 | 1.134.266 | |
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -362.806 | 2.736.644 | -11,71 | 1,49 | -540.291 | 4.075.410 | |
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -192.293 | 988.387 | -16,29 | 1,53 | -294.824 | 1.515.395 | |
| 2025-09-18 |
|
4 | LVTX |
LAVA Therapeutics NV
Common Stock |
S - Sale | -307.707 | 3.099.450 | -9,03 | 1,53 | -471.776 | 4.752.077 | |
| 2025-02-06 | 3 | LVTX |
LAVA Therapeutics NV
Common Shares |
3.407.157 | ||||||||
| 2025-02-06 | 3 | LVTX |
LAVA Therapeutics NV
Common Shares |
1.180.680 | ||||||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -15.600 | 1.573.453 | -0,98 | 9,41 | -146.793 | 14.805.878 | |
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -52.305 | 1.589.053 | -3,19 | 9,08 | -475.008 | 14.430.985 | |
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -5.454 | 0 | -100,00 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | 5.454 | 5.454 | |||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -5.499 | 0 | -100,00 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | 5.499 | 5.499 | |||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -366.590 | 1.641.358 | -18,26 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -17.595 | 0 | -100,00 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | 17.595 | 17.595 | |||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -20.397 | 0 | -100,00 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | 20.397 | 20.397 | |||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
J - Other | -1.019.867 | 4.079.469 | -20,00 | ||||
| 2024-10-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -89.990 | 2.007.948 | -4,29 | 9,66 | -869.240 | 19.395.372 | |
| 2024-09-24 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -1.132.566 | 5.099.336 | -18,17 | 6,53 | -7.395.203 | 33.296.624 | |
| 2024-09-13 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -9.269 | 6.231.902 | -0,15 | 6,16 | -57.100 | 38.390.386 | |
| 2024-09-13 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -16.047 | 6.241.171 | -0,26 | 6,00 | -96.309 | 37.457.636 | |
| 2024-09-13 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
S - Sale | -541.897 | 6.257.218 | -7,97 | 6,00 | -3.251.382 | 37.543.308 | |
| 2024-04-11 |
|
4 | CTNM |
Contineum Therapeutics, Inc.
Class A Common Stock |
C - Conversion | 148.312 | 148.312 | |||||
| 2024-04-11 |
|
4 | CTNM |
Contineum Therapeutics, Inc.
Class A Common Stock |
C - Conversion | 2.531 | 2.531 | |||||
| 2024-04-11 |
|
4 | CTNM |
Contineum Therapeutics, Inc.
Class A Common Stock |
C - Conversion | 391.785 | 391.785 | |||||
| 2024-04-04 | 3 | CTNM |
Contineum Therapeutics, Inc.
Class A Common Stock |
375.535 | ||||||||
| 2023-01-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
U - Other | -1.003.658 | 0 | -100,00 | ||||
| 2023-01-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
U - Other | -2.465 | 0 | -100,00 | ||||
| 2023-01-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
U - Other | -414.607 | 0 | -100,00 | ||||
| 2023-01-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
U - Other | -2.236.888 | 0 | -100,00 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -10.099 | 0 | -100,00 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 10.099 | 10.099 | |||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -46.753 | 64.731 | -41,94 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -141.103 | 0 | -100,00 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 4.419 | 141.103 | 3,23 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -20.454 | 28.322 | -41,93 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 3.992 | 136.684 | 3,01 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -18.478 | 25.587 | -41,93 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 132.692 | 132.692 | |||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -614.315 | 850.560 | -41,94 | ||||
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -33.395 | 111.484 | -23,05 | 12,25 | -409.146 | 1.365.869 | |
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -14.611 | 48.776 | -23,05 | 12,25 | -179.010 | 597.589 | |
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -13.199 | 44.065 | -23,05 | 12,25 | -161.710 | 539.871 | |
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -438.795 | 1.464.875 | -23,05 | 12,25 | -5.375.985 | 17.947.209 | |
| 2022-06-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
S - Sale | -250.000 | 2.344.451 | -9,64 | 12,25 | -3.062.925 | 28.723.510 | |
| 2022-01-07 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | X | -1.261 | 2.465 | -33,84 | |||
| 2022-01-07 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -51.556 | 0 | -100,00 | ||||
| 2022-01-07 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 51.556 | 51.556 | |||||
| 2022-01-07 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | X | -200.213 | 414.607 | -32,56 | |||
| 2021-12-23 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | X | -1.261 | 3.726 | -25,29 | |||
| 2021-12-23 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -51.556 | 0 | -100,00 | ||||
| 2021-12-23 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 51.556 | 51.556 | |||||
| 2021-12-23 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | X | -200.213 | 614.820 | -24,57 | |||
| 2021-10-20 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
S - Sale | X | -1.531 | 4.987 | -23,49 | 15,09 | -23.109 | 75.273 |
| 2021-10-20 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
S - Sale | X | -242.943 | 815.033 | -22,96 | 15,09 | -3.666.957 | 12.302.027 |
| 2021-10-20 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
S - Sale | X | -1.912 | 6.518 | -22,68 | 14,63 | -27.978 | 95.376 |
| 2021-10-20 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
S - Sale | X | -303.614 | 1.057.976 | -22,30 | 14,63 | -4.442.693 | 15.481.045 |
| 2021-08-09 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -2.260 | 0 | -100,00 | ||||
| 2021-08-09 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 2.260 | 2.260 | |||||
| 2021-08-09 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -2.279 | 0 | -100,00 | ||||
| 2021-08-09 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 2.279 | 2.279 | |||||
| 2021-08-09 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -152.071 | 231.211 | -39,68 | |||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Series C convertible preferred stock |
C - Conversion | -2.699.328 | 0 | -100,00 | ||||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Series B convertible preferred stock |
C - Conversion | -4.150.000 | 0 | -100,00 | ||||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Series B convertible preferred stock |
C - Conversion | -3.000.000 | 0 | -100,00 | ||||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Series A convertible preferred stock |
C - Conversion | -20.004.280 | 0 | -100,00 | ||||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
P - Purchase | 157.895 | 2.097.938 | 8,14 | 19,00 | 3.000.005 | 39.860.822 | |
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
C - Conversion | 1.940.043 | 1.940.043 | |||||
| 2021-06-30 |
|
4 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
C - Conversion | 6.515.869 | 6.799.115 | 2.300,43 | ||||
| 2021-06-23 | 3 | GLUE |
Monte Rosa Therapeutics, Inc.
Common Stock |
283.246 | ||||||||
| 2021-06-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -1.119 | 0 | -100,00 | ||||
| 2021-06-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1.119 | 1.119 | |||||
| 2021-06-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -1.128 | 0 | -100,00 | ||||
| 2021-06-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1.128 | 1.128 | |||||
| 2021-06-03 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -75.000 | 383.282 | -16,37 | ||||
| 2021-05-14 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -2.018 | 8.430 | -19,31 | ||||
| 2021-05-14 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -82.486 | 0 | -100,00 | ||||
| 2021-05-14 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 82.486 | 82.486 | |||||
| 2021-05-14 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -320.340 | 1.361.590 | -19,05 | ||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -3.473 | 0 | -100,00 | ||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 3.473 | 3.473 | |||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -16.079 | 144.879 | -9,99 | |||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -48.528 | 0 | -100,00 | ||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1.520 | 48.528 | 3,23 | ||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -7.035 | 63.387 | -9,99 | |||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1.373 | 47.008 | 3,01 | ||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -6.355 | 57.264 | -9,99 | |||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 45.635 | 45.635 | |||||
| 2021-05-07 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -211.277 | 1.903.670 | -9,99 | |||
| 2021-03-30 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -1.990 | 10.448 | -16,00 | ||||
| 2021-03-30 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -82.491 | 0 | -100,00 | ||||
| 2021-03-30 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 82.491 | 82.491 | |||||
| 2021-03-30 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -320.368 | 1.681.930 | -16,00 | ||||
| 2021-02-19 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -5.607 | 0 | -100,00 | ||||
| 2021-02-19 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 5.607 | 5.607 | |||||
| 2021-02-19 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | -6.500 | 0 | -100,00 | ||||
| 2021-02-19 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | 6.500 | 6.500 | |||||
| 2021-02-19 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock |
J - Other | X | -325.000 | 2.236.888 | -12,69 | |||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -745 | 0 | -100,00 | ||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 745 | 745 | |||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -751 | 0 | -100,00 | ||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 751 | 751 | |||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -50.000 | 458.282 | -9,84 | |||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -5.176 | 0 | -100,00 | ||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 5.176 | 5.176 | |||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -6.000 | 0 | -100,00 | ||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 6.000 | 6.000 | |||||
| 2021-02-18 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -300.000 | 2.594.451 | -10,36 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -745 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 745 | 745 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -751 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 751 | 751 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -50.000 | 508.282 | -8,96 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -4.313 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 4.313 | 4.313 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -5.000 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 5.000 | 5.000 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -250.000 | 2.894.451 | -7,95 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -4.328 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 4.328 | 4.328 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -20.037 | 160.958 | -11,07 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -60.472 | 0 | -100,00 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1.893 | 60.472 | 3,23 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -8.766 | 70.422 | -11,07 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1.711 | 58.579 | 3,01 | ||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -7.919 | 63.619 | -11,07 | |||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 56.868 | 56.868 | |||||
| 2021-02-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -263.278 | 2.114.947 | -11,07 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -745 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 745 | 745 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -751 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 751 | 751 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -50.000 | 558.282 | -8,22 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -4.744 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 4.744 | 4.744 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -5.500 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 5.500 | 5.500 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -275.000 | 3.144.451 | -8,04 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -1.388 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1.388 | 1.388 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -11.688 | 180.995 | -6,07 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | -35.276 | 0 | -100,00 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 1.105 | 35.276 | 3,23 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -5.113 | 79.188 | -6,07 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 998 | 34.171 | 3,01 | ||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -4.620 | 71.538 | -6,07 | |||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | 33.173 | 33.173 | |||||
| 2021-01-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -153.579 | 2.378.225 | -6,07 | |||
| 2020-12-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -21.707 | 192.683 | -10,13 | |||
| 2020-12-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -9.497 | 84.301 | -10,12 | |||
| 2020-12-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -8.579 | 76.158 | -10,12 | |||
| 2020-12-17 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
J - Other | X | -285.217 | 2.531.804 | -10,12 | |||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Simple Agreement for Future Equity |
C - Conversion | -333.333 | 0 | -100,00 | ||||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1.245.330 | 0 | -100,00 | ||||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1.745.458 | 0 | -100,00 | ||||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -14.452.795 | 0 | -100,00 | ||||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Common Stock |
C - Conversion | 577.544 | 577.544 | |||||
| 2020-07-21 |
|
4 | PAND |
Pandion Therapeutics, Inc.
Common Stock |
C - Conversion | 3.176.507 | 3.176.507 | |||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -458.282 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -875.568 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -3.350 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -3.708 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -8.475 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -111.361 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -2.443.883 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -61.791 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -68.398 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -156.335 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class A Preferred Shares |
C - Conversion | -2.054.198 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
P - Purchase | 100.000 | 3.419.451 | 3,01 | 20,00 | 2.000.000 | 68.389.020 | |
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
P - Purchase | 150.000 | 608.282 | 32,73 | 20,00 | 3.000.000 | 12.165.640 | |
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 458.282 | 458.282 | |||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 875.568 | 3.319.451 | 35,83 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 3.350 | 84.737 | 4,12 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 3.708 | 93.798 | 4,12 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 8.475 | 214.390 | 4,12 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 111.361 | 2.817.021 | 4,12 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 2.443.883 | 2.443.883 | |||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 61.791 | 81.387 | 315,32 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 68.398 | 90.090 | 315,31 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 156.335 | 205.915 | 315,32 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Shares |
C - Conversion | 2.054.198 | 2.705.660 | 315,32 | ||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
1.393.792 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
791.910 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
764.022 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
761.926 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
1.393.792 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
791.910 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
764.022 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
761.926 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
1.393.792 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
791.910 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
764.022 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
761.926 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
1.393.792 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
791.910 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
764.022 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
761.926 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
1.393.792 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
791.910 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
764.022 | ||||||||
| 2020-06-18 | 3 | RPTX |
Repare Therapeutics Inc.
Common Shares |
761.926 | ||||||||
| 2020-05-20 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
J - Other | -1.734 | 0 | -100,00 | ||||
| 2020-05-20 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
J - Other | 1.734 | 1.734 | |||||
| 2020-05-20 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
J - Other | -1.750 | 0 | -100,00 | ||||
| 2020-05-20 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
J - Other | 1.750 | 1.750 | |||||
| 2020-05-20 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
J - Other | -116.664 | 216.669 | -35,00 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Series B Preferred Stock |
C - Conversion | -708.352 | 0 | -100,00 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1.049.175 | 0 | -100,00 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Series A-1 Preferred Stock |
C - Conversion | -2.977.242 | 0 | -100,00 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 225.000 | 933.352 | 31,76 | 18,00 | 4.050.000 | 16.800.336 | |
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
C - Conversion | 708.352 | 708.352 | |||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
C - Conversion | 1.049.175 | 4.026.417 | 35,24 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
C - Conversion | 2.977.242 | 2.977.242 | |||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -566.158 | 0 | -100,00 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -495.388 | 0 | -100,00 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1.941.500 | 0 | -100,00 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1.654.359 | 0 | -100,00 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -10.420 | 0 | -100,00 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
P - Purchase | 437.500 | 1.003.658 | 77,28 | 16,00 | 7.000.000 | 16.058.528 | |
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 566.158 | 566.158 | |||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
P - Purchase | 125.000 | 2.561.888 | 5,13 | 16,00 | 2.000.000 | 40.990.208 | |
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 495.388 | 2.436.888 | 25,52 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 1.941.500 | 1.941.500 | |||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
P - Purchase | 27.500 | 2.002.298 | 1,39 | 16,00 | 440.000 | 32.036.768 | |
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 1.654.359 | 1.974.798 | 516,28 | ||||
| 2019-11-04 |
|
4 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
C - Conversion | 10.420 | 12.438 | 516,35 | ||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324.475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642.896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324.475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642.896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324.475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642.896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324.475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642.896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324.475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642.896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324.475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642.896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324.475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642.896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324.475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642.896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324.475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642.896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324.475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642.896 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
324.475 | ||||||||
| 2019-10-30 | 3 | OYST |
Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share |
642.896 | ||||||||
| 2019-10-07 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -512.995 | 0 | -100,00 | ||||
| 2019-10-07 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.993.658 | 0 | -100,00 | ||||
| 2019-10-07 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
P - Purchase | 333.333 | 333.333 | 15,00 | 4.999.995 | 4.999.995 | ||
| 2019-10-07 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
C - Conversion | 512.995 | 2.519.323 | 25,57 | ||||
| 2019-10-07 |
|
4 | APRE |
Aprea Therapeutics, Inc.
Common Stock |
C - Conversion | 1.993.658 | 2.006.328 | 15.735,26 |
